Syed Mohi Ahmed, MD, PhD
LightNews LightNews
banner
smohahm.bsky.social
Syed Mohi Ahmed, MD, PhD
@smohahm.bsky.social
43 followers 54 following 47 posts

Medical Oncologist, follows GU, lung, head and neck and gastroesophageal cancers on BlueSky

Medical Director, Northwestern Medicine Oak Brook Cancer Center. Views are personal
Posts Replies Media Videos
smohahm.bsky.social
Bishal Gyawali makes "a case for using superiority design to test de-escalation strategies. This will avoid the limitations of non-inferiority design and make de-escalation strategies more efficient to test."
De-escalation trials do not always need to be non-inferiority- A case for superiority design de-escalation trials in oncology
Abstract. De-escalation trials in oncology have received increased attention recently because there is a growing concern that patients with cancer are bein
academic.oup.com
November 10, 2025 at 12:56 PM
Reposted by Syed Mohi Ahmed, MD, PhD
nejm.org
At 23 years of follow-up, population-based PSA screening of asymptomatic men led to a sustained reduction in prostate cancer mortality, although overdiagnosis remains a concern. Full ERSPC study results: nej.md/42YYsg7

#MedSky #Oncology
Original Article | Oct 30, 2025 European Study of Prostate Cancer Screening — 23-Year Follow-up Figure 2B. Prostate Cancer–Specific Mortality. The NEJM identity sits at the bottom.
October 29, 2025 at 9:40 PM
Reposted by Syed Mohi Ahmed, MD, PhD
nejm.org
3️⃣ Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer (EMBARK trial) nej.md/4h8QpDc

𝗡𝗼𝘁𝗮𝗯𝗹𝗲 𝗵𝗲𝗮𝗱𝗹𝗶𝗻𝗲:
Prostate Cancer: Drug Combo Lowers Death Risk by 40% in Aggressive Cases (Newsweek) nej.md/47ztwoa
Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer | NEJM
In the phase 3 EMBARK trial, enzalutamide plus leuprolide and enzalutamide monotherapy were associated with longer metastasis-free survival than leuprolide alone among patients with biochemically r...
nej.md
October 31, 2025 at 3:08 PM
Reposted by Syed Mohi Ahmed, MD, PhD
myesmo.bsky.social
#ESMO25: Enzalutamide failed to deliver in high-risk localised #ProstateCancer in the ENZARAD trial, but improved OS, with leuprolide, in biochemically recurrent prostate cancer in the final OS analysis of EMBARK.
#ESMODailyReporter➡️ https://ow.ly/XCPX50XeO8K

Alison Tree
October 22, 2025 at 8:00 AM
Reposted by Syed Mohi Ahmed, MD, PhD
myesmo.bsky.social
#ESMO25: 177Lu-PSMA-617 with ADT plus ARPI showed PFS benefit in hormone-sensitive #ProstateCancer (#HSPC) but no improvement seen with 177Lu-PSMA-617 vs docetaxel in castration-resistant prostate cancer (#mCRPC) after ARPI.
#ESMODailyReporter ➡️ https://ow.ly/2C0e50XeAoj

October 19, 2025 at 3:45 PM
smohahm.bsky.social
Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study www.thelancet.com/journals/lan...
Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303...
Tarlatamab plus a PD-L1 inhibitor as maintenance after first-line chemo-immunotherapy showed a manageable safety profile with promising anticancer activity, supporting the ongoing phase 3 trial (NCT06...
www.thelancet.com
October 22, 2025 at 12:27 AM
smohahm.bsky.social
Metastasis-directed radiotherapy without systemic therapy for oligometastatic clear-cell renal-cell carcinoma: primary efficacy analysis of a single-arm, single-centre, phase 2 trial - The Lancet Oncology www.thelancet.com/journals/lan...
Metastasis-directed radiotherapy without systemic therapy for oligometastatic clear-cell renal-cell carcinoma: primary efficacy analysis of a single-arm, single-centre, phase 2 trial
Select patients with oligometastatic disease can be managed with serial metastasis-directed therapy with prolonged time off systemic therapy, favourable progression-free survival, and limited adverse ...
www.thelancet.com
October 22, 2025 at 12:25 AM
smohahm.bsky.social
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer | New England Journal of Medicine www.nejm.org/doi/full/10....
www.nejm.org
October 22, 2025 at 12:18 AM
smohahm.bsky.social
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR-Mutated Advanced NSCLC | New England Journal of Medicine www.nejm.org/doi/full/10....
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR-Mutated Advanced NSCLC | NEJM
Sacituzumab tirumotecan (sac-TMT) is an antibody–drug conjugate targeting trophoblast cell-surface antigen 2 that has shown significant survival benefits in patients with EGFR-mutated non–small-cel...
www.nejm.org
October 22, 2025 at 12:17 AM
smohahm.bsky.social
Great result

ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer | New England Journal of Medicine www.nejm.org/doi/full/10....
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer | NEJM
Patients with muscle-invasive bladder cancer have varied outcomes after cystectomy. Circulating tumor DNA (ctDNA)–based detection of molecular residual disease may identify patients at high risk fo...
www.nejm.org
October 22, 2025 at 12:10 AM
Reposted by Syed Mohi Ahmed, MD, PhD
myesmo.bsky.social
#ESMO25: Atezolizumab prolonged DFS in #ctDNA+ muscle-invasive #BladderCancer in the IMvigor011 #ClinicalTrial, providing first evidence in support of minimal residual disease-guided adjuvant #immunotherapy in this setting.
#ESMODailyReporter ➡️ https://ow.ly/ythW50XeYRP

October 20, 2025 at 2:47 PM
Reposted by Syed Mohi Ahmed, MD, PhD
myesmo.bsky.social
#ESMO25: Use of #ctDNA as a decision-making aid to guide adjuvant chemotherapy may not be ready for prime time in #ColonCancer as two #ClinicalTrials fail to meet their primary endpoints. Read more in the #ESMODailyReporter ➡️ https://ow.ly/OFmM50XeZaZ

#LiquidBiopsy
October 20, 2025 at 3:10 PM
Reposted by Syed Mohi Ahmed, MD, PhD
myesmo.bsky.social
#ESMO25: Phase III FORTITUDE-101 #ClinicalTrial reports improved short-term survival with first-in-class FGFR2b inhibitor bemarituzumab added to chemotherapy to treat FGFR2b-overexpressing #Gastric or #GEJCancer.
More in the #ESMODailyReporter ➡️ https://ow.ly/C2MU50Xf08l
October 20, 2025 at 4:02 PM
Reposted by Syed Mohi Ahmed, MD, PhD
myesmo.bsky.social
#ESMO25: First-line ivonescimab, a bispecific antibody targeting PD-1 and VEGF, plus chemotherapy improved progression-free survival vs tislelizumab plus chemotherapy in patients with squamous #NSCLC in the phase III HARMONi-6 trial.
#ESMODailyReporter 🔗 https://ow.ly/wl7X50XeA1o

October 19, 2025 at 2:45 PM
Reposted by Syed Mohi Ahmed, MD, PhD
myesmo.bsky.social
#ESMO25: OS was significantly improved w/ the #ADC disitamab vedotin plus #immunotherapy w/ toripalimab vs chemotherapy in first-line advanced HER2-expressing #UrothelialCarcinoma in the RC48-C016 #ClinicalTrial.
#ESMODailyReporter 🔗 https://ow.ly/ZS9V50XeAsN

October 19, 2025 at 4:15 PM
smohahm.bsky.social
The combination of enfortumab vedotin (EV) – an antibody–drug conjugate – and pembrolizumab, before and after standard radical cystectomy and pelvic lymph node dissection, may be a potential new standard of care for cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC)
#esmo25
Peri-operative enfortumab vedotin plus pembrolizumab prolongs survival in muscle-invasive bladder cancer
In KEYNOTE-905/EV-303, the combination of an antibody–drug conjugate and immunotherapy showed statistically significant and clinically meaningful improvements in event-free survival and overall surviv...
dailyreporter.esmo.org
October 20, 2025 at 2:14 AM
smohahm.bsky.social
Five-year results confirm durable DFS benefit and consistent safety profile for adjuvant nivolumab in high-risk MIUC. Post-hoc exploratory ctDNA assessment identified patients at highest risk of recurrence. www.annalsofoncology.org/article/S092...
Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274
Despite surgery, recurrence rates remain high in muscle-invasive urothelial carcinoma (MIUC). The phase III randomized, double-blind, multicenter CheckMate 274 trial comparing adjuvant nivolumab versu...
www.annalsofoncology.org
October 20, 2025 at 2:06 AM
smohahm.bsky.social
Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 Phase III study - Annals of Oncology www.annalsofoncology.org/article/S092...
Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 Phase III study
In metastatic hormone-sensitive prostate cancer (mHSPC), PTEN deficiency results in PI3K/AKT pathway activation, providing an independent proliferative drive, which cannot be suppressed by androgen re...
www.annalsofoncology.org
October 20, 2025 at 2:04 AM
Reposted by Syed Mohi Ahmed, MD, PhD
mathewgwilson.bsky.social
#FLAURA2 analysis of exploratory subgroups shows mOS benefit in:

🧠 brain mets (40.9 v 29.7months)
🥃liver mets (36.6 vs 28months)
🦴bone mets (40.2 va 32.3 months)
🧬ctDNA positive (38.4 vs 32.5 months)

Confirms #FLAURA2 approch valid as a SOC in these groups #ESMO25 #LCSM
October 17, 2025 at 3:46 PM
Reposted by Syed Mohi Ahmed, MD, PhD
nejm.org
In high-risk biochemically recurrent prostate cancer, enzalutamide plus leuprolide significantly improved overall survival as compared with leuprolide alone. Enzalutamide monotherapy had no significant benefit for survival. Full EMBARK phase 3 trial results: nej.md/4h8QpDc

#ESMO25
Kaplan–Meier curves for overall survival, assessed in a time-to-event analysis from randomization to death from any cause, in the combination group as compared with the leuprolide-alone group
October 19, 2025 at 8:20 AM
Reposted by Syed Mohi Ahmed, MD, PhD
nejm.org
In untreated, advanced triple-negative breast cancer, sacituzumab govitecan led to significantly longer progression-free survival than chemotherapy (9.7 months vs. 6.9 months). Full ASCENT-03 phase 3 trial results: nej.md/4ncuUCV

#ESMO25
European Society for Medical Oncology Original Article | October 19, 2025 | NEJM.org Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer Figure 1A. Progression-free Survival.
October 19, 2025 at 6:35 AM
Reposted by Syed Mohi Ahmed, MD, PhD
oncoalert.bsky.social
Welcome to #ESMO25: The OncoAlert #LungCancer Faculty, led by Dr.Hidehito Hironouchi 🇯🇵 as well as Dr Biagio Ricciuti 🇺🇸 and Dr. Gil Morgan🇺🇸 , have selected the OncoAlert🚨 TOP 🔟 #LungCancer Abstracts to be presented at #ESMO25 in Berlin 🇩🇪 Picked using a Delphi System to establish our picks. #NSCLC
October 17, 2025 at 9:00 AM
Reposted by Syed Mohi Ahmed, MD, PhD
rielymd.bsky.social
Useful trial shows value of supportive measures for amivantamab tolerance (doxycycline or minocycline, clindamycin, chlorhexidine (on nails), and ceramide-based moisturizer www.jto.org/article/S155...
Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial
Amivantamab plus lazertinib significantly improved progression-free and overall survival versus osimertinib in patients with previously untreated, EGFR-mutant advanced NSCLC. EGFR-targeted therapies a...
www.jto.org
September 22, 2025 at 9:42 PM
Reposted by Syed Mohi Ahmed, MD, PhD
cancercommunicator.com
At #WCLC25 results of #FLAURA2 showed a 47.5 mo mOS w/ osimertinib+chemo in pts w/ advanced EGFRm+ NSCLC vs 37.6 with osi monotherapy. Benefit seen across subgroups. Longer chemo-free period with combo. #LCSM #LungCancer #NSCLC #oncsky #cansky
September 8, 2025 at 8:04 PM
Reposted by Syed Mohi Ahmed, MD, PhD
pearlf.bsky.social
The median overall survival of nearly 4 years appears to be the longest benefit ever reported in a global Phase III clinical trial #FLAURA2 in EGFR-mutated advanced lung cancer #WCLC25 #NSCLC #lcsm #medsky #biosky
pearlf.bsky.social Pearl Freier @pearlf.bsky.social · Sep 7
AstraZeneca's cancer drug Tagrisso in combination w/ chemotherapy showed median overall survival/OS of nearly 4 yrs in Phase 3 trial #FLAURA2 in EGFR-mutated advanced non-small cell lung cancer. Below is Penn Medicine medical oncologist & #lcsm expert's tweets from #WCLC25 #NSCLC #medsky #biosky
September 7, 2025 at 1:56 PM